“Cancer can touch you, but not your soul; neither your thoughts, nor your heart.” "There is no medicine like hope, no incentive so great, and no tonic so powerful as expectation of something tomorrow”
One in eight women develops breast cancer over the course of their lifetime. What if we say its early detection is possible now?..
Breast Pathology 2019 through its 2 days summit will dream of a planet where you can detect issues early and can use that information to make changes that are beneficial for everyone. 


Hilaris Conferences is hosting the International Conferences, Workshops, Symposiums, Meetings, and Events in the vast domains of Clinical, Medical,Life Sciences, Pharmaceuticals, Environmental Sciences, Agriculture & Food, Healthcare, and Applied Engineering etc. Hilaris Conferences, we will provide a great platform for the Oncologist, Breast Pathologists, learners, researchers, Students, policymakers, and medical advocates to share knowledge and explore your network according to your field.

 We cordially welcome you to be a part of the Hilaris Conference and share your knowledge for a wonderful future. We look for the support from all our stakeholders to live up to our vision "Join us as a Lerner and proceed as a Leader".

Pathology is significant in modern medical diagnosis and research by looking at tissue from the body. Breast cancer is the most diagnosed cancer in women worldwide and is increasing particularly in developing countries. Starting from a particular section, breast Cancer can spread to different parts of the breast. Breast cancers can be divided into two main types: the carcinomas and the sarcomas. Carcinomas are cancers that arise from the epithelial component of the breast and sarcoma arises from the connective tissue of the body.

Most of the important information about breast cancer will come from your pathology report and these Reports of a breast cancer can be studied based on hormone receptor status, human epidermal growth factor, Grade, Malignant, tumors. Here are many factors that may affect their choice of treatment. Treatment of breast cancer depends on the type of cancer and its stage (0-IV) and may involve surgery, radiation, or chemotherapy for Breast Cancer, Hormone Therapy for Breast Cancer, Targeted therapy for Breast Cancer.

The breast cancer treatment market was valued around USD 12,300 Mn in 2017 and is expected to cross USD 19,000 Mn by 2025. According to market professionals, these upcoming medications assure to provide enhanced efficiency, shorter onset of action and fewer side effects as compared to the currently available breast cancer treatment. Thus, future prospect of these molecules during the forecast period 2016 - 2022 is projected to have a insightful impact on the growth of the overall breast cancer treatment market.

The future of breast cancer pathology will be a blend of detailed and accurate histologic calculation, plus sophisticated molecular biomarker testing, to ensure that patients are not over- or undertreated, but instead receive the most optimal targeted therapy for their disease.

People who can attend as an audience at Breast Pathology 2019

  • Pathologists
  • Noble laureates in Health Care and Medicine
  • Directors, CEO’s of Organizations
  • Breast Cancer surgeons
  • Doctors
  • Researchers
  • Professors
  • PhD scholars
  • Scientists
  • Medical colleges and universities
  • Breast Cancer Advocates
  • Medicine Experts
  • Business Professionals
  • Breast Pathology Societies and Associations
  • Breast Radiologists and physicians


University of Nottingham

University of Southampton

University of Liverpool  

University of Birmingham 

University of Dundee       

University of Chicago

University of Kansas

University of Iowa Hospitals & Clinics

University of Wisconsin-Madison

University of Michigan

Central Washington University

Seoul National University Hospital

Peking University

University of Hong Kong

Seoul National University

University of Sydney



European Society of Pathology 

British Division of the International Academy of Pathology

National Comprehensive Cancer Network 

European Commission Initiative on Breast Cancer

European Breast Cancer Council (EBC council)   

The American Society of Breast Surgeons

United States and Canadian Academy of Pathology

Association for Molecular Pathology

National Breast Cancer Foundation

Living Beyond Breast Cancer (LBBC)

Breast cancer in Asia

Franciscan Surgical Associates

International Academy of Pathology

Assembly of Asia Pacific International Academy of Pathology


M.D. Anderson Cancer Center

Memorial Sloan Kettering Hospital

Mayo Clinic

Dana-Farber Cancer Institute

Seattle Cancer Care Alliance

Johns Hopkins Hospital                       

St Helens Hospital

Massachusetts General Hospital

Oxford University Hospitals

The Royal Liverpool and Broadgreen University Hospitals

Cambridge University Hospitals

Teladoc Health

Nuffield Health Bristol Hospital

St Vincent’s Private Hospital

Macquarie University Hospital

Fiona Stanley Hospital


Join Our Newsletter